Market Cap
$7.8B
PRAX
Praxis Precision Medicines, Inc.
$292.07 ▲ +1.80%
Prev close $286.91Market cap$7.8B
ConsensusStrong Buy
12-mo target$643.58 (+120.4%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (8/10)37 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PRAX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$8.6B
Inst. Activity
37 buys / 13 sells
Insider Activity
$0.00 buy / $3.6M sell
Insider Net $
-$3.6M
Social Sentiment
50° Neutral
SEC Reports
6
Press Releases
4
Price chart 30d -18.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jan 29, 2027 fda_pdufa
PDUFA: PRAX — ulixacaltamide in Essential Tremor — 2027-01-29
FDA target action date 2027-01-29 for PRAX (Praxis Precision Medicines, Inc.). Drug: ulixacaltamide.
Jul 8, 2026 Insider
Souza Marcio gifted 2,600 shares
Chief Executive Officer
Jul 8, 2026 Insider
Souza Marcio gifted 20,521 shares
Chief Executive Officer
Jun 30, 2026 Inst.
Orbis Allan Gray Ltd — TRIM
1,529,788 shares ($512.2M)
Jun 30, 2026 Inst.
Jun 29, 2026 SEC VANGUARD PORTFOLIO MANAGEMENT LLC — ADD
1,335,185 shares ($447.0M)
Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its relutrigine NDA (SC
8-K — Impact 6/10
Jun 24, 2026 Insider
Jun 11, 2026 SEC DeSimone Jill acquired via exercise 8,566 shares
Director @ $44.25 ($379.0K)
Three institutional investors added $58.3M to PRAX positions in Q3 2025, led by Point72's $39.2M increase, while two sel
INST-CLUSTER — Impact 4/10
Analyst ratings buy % -2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 25 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 24, 2026 | Needham | REITERATE | Buy | 50% |
| Aug 21, 2026 | Goldman Sachs | MAINTAIN | Buy | 54% |
| Aug 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 7, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Aug 6, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 29, 2026 | BTIG | REITERATE | Buy | 53% |
| Jul 13, 2026 | Goldman Sachs | INITIATE | Buy | 54% |
| Jun 29, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jun 18, 2026 | RBC Capital | INITIATE | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 13 | 2 | 0 | 1 | 88% | |
| Aug 1, 2026 | 9 | 13 | 2 | 0 | 1 | 88% | |
| Jul 1, 2026 | 9 | 12 | 2 | 0 | 1 | 88% | |
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 1 | 87% | |
| May 1, 2026 | 9 | 11 | 2 | 0 | 1 | 87% | |
| Apr 1, 2026 | 8 | 11 | 2 | 0 | 1 | 86% | |
| Mar 1, 2026 | 8 | 12 | 2 | 0 | 1 | 87% | |
| Feb 1, 2026 | 7 | 12 | 1 | 0 | 1 | 90% |
Price targets
Where 19 covering analysts think PRAX trades over the next 12 months.
$643.58 +120.4% upside Strong Buy
Current$292.07 Low$188.00 Median$575.00 High$1,201.00 19 analysts
$188.00$1,201.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood -10.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 3 bullish, 1 bearish, 1 mixed, 1 neutral · avg impact 5.7/10.Plus 4 press releases.
BEARISH8-K6/10
Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its
Jun 29, 2026
MIXEDINST-CLUSTER4/10
Three institutional investors added $58.3M to PRAX positions in Q3 2025, led by Point72's $39.2M inc
Jun 11, 2026
BULLISHPRESS-RELEASE8/10
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68
May 7, 2026
NEUTRALPRESS-RELEASE2/10
Praxis Precision Medicines issued a press release announcing its Q1 2026 earnings report will be pub
May 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jan 29, 2027
fda_pdufa
PDUFA: PRAX — ulixacaltamide in Essential Tremor — 2027-01-29
FDA target action date 2027-01-29 for PRAX (Praxis Precision Medicines, Inc.). Drug: ulixacaltamide. Indication: Essential Tremor. FDA accepted NDA fo
Dec 27, 2026
fda_pdufa
PDUFA: PRAX — relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies — 2026-12-27
FDA target action date 2026-12-27 for PRAX (Praxis Precision Medicines, Inc.). Drug: relutrigine. Indication: SCN2A and SCN8A developmental and epilep
Sep 27, 2026
fda_pdufa
PDUFA: PRAX — relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies — 2026-09-27
FDA target action date 2026-09-27 for PRAX (Praxis Precision Medicines, Inc.). Drug: relutrigine. Indication: SCN2A and SCN8A developmental and epilep
Sep 8, 2026
Clinical Trial
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 8, 2026
clinical_trial_readout
T-90d Trial Readout: 1.0mg/kg/day PRAX-562 (Phase 3)
Trial: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine Sponsor: Praxis Precision Medicines
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-3.63 | $-5.60–$-2.74 | -8.1% | +0.0% | 12↑ 4↓ | $0.0B | 17 |
| Next Q | $-4.21 | $-7.96–$-3.26 | -20.3% | +0.0% | 8↑ 8↓ | $0.0B | 17 |
| Current FY | $-13.94 | $-19.83–$-12.07 | -3.4% | +0.0% | 15↑ 1↓ | $0.0B | 17 |
| Next FY | $-9.29 | $-17.06–$5.36 | 33.3% | +3.8% | 7↑ 7↓ | $0.3B | 16 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-3.632 | — |
| 7d ago | $-3.632 | — |
| 30d ago | $-3.632 | — |
| 60d ago | $-4.026 | +0.394 |
| 90d ago | $-4.025 | +0.394 |
Institutional ownership
Which big funds own PRAX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $8.6B total value (25,711,148 shares) as of 2026-Q2. Top holders: NOMURA, Jupiter, FMR. Net buying activity: 37 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| Jupiter Topco LLC | 3,421,374 | $1.1B | 13.3% | — |
| FMR LLC | 2,316,907 | $775.7M | 9.0% | — |
| BlackRock, Inc. | 2,292,585 | $767.5M | 8.9% | — |
| BAKER BROS. ADVISORS LP | 1,753,198 | $587.0M | 6.8% | — |
| Orbis Allan Gray Ltd | 1,529,788 | $512.2M | 5.9% | TRIM -38.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,335,185 | $447.0M | 5.2% | ADD +76.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,235,299 | $413.6M | 4.8% | — |
| STATE STREET CORP | 1,026,443 | $343.7M | 4.0% | — |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,015,480 | $340.0M | 3.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Orbis Allan Gray Ltd | TRIM | 2,472,480 | 1,529,788 | -38.1% | $512.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 756,748 | 1,335,185 | +76.4% | $447.0M |
| NORGES BANK | NEW | — | 346,969 | — | $116.2M |
| Polar Capital Holdings Plc | NEW | — | 279,131 | — | $93.5M |
| AMERICAN CENTURY COMPANIES INC | ADD | 128,254 | 237,315 | +85.0% | $79.5M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | DOUBLED | 662 | 218,898 | +32966.2% | $73.3M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 143,082 | 188,409 | +31.7% | $63.1M |
| MARSHALL WACE, LLP | DOUBLED | 45,149 | 137,008 | +203.5% | $45.9M |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 174,350 | 125,867 | -27.8% | $42.1M |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 28,134 | 122,227 | +334.4% | $40.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 43 transactions. Net -$3.6M — $0.00 bought, $3.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Souza Marcio | Chief Executive Officer | GIFT | 2,600 | — | — |
| Jul 8, 2026 | Souza Marcio | Chief Executive Officer | GIFT | 20,521 | — | — |
| Jun 24, 2026 | DeSimone Jill | Director | EXERCISE | 8,566 | $44.25 | $379.0K |
| Jun 24, 2026 | DeSimone Jill | Director | SELL | 10 | $301.44 | $3.0K |
| Jun 24, 2026 | DeSimone Jill | Director | EXERCISE | 3,034 | $147.30 | $446.9K |
| Jun 24, 2026 | DeSimone Jill | Director | SELL | 120 | $303.13 | $36.4K |
| Jun 24, 2026 | DeSimone Jill | Director | SELL | 320 | $305.31 | $97.7K |
| Jun 24, 2026 | DeSimone Jill | Director | SELL | 683 | $306.77 | $209.5K |
| Jun 24, 2026 | DeSimone Jill | Director | SELL | 1,240 | $308.24 | $382.2K |
| Jun 24, 2026 | DeSimone Jill | Director | SELL | 999 | $309.38 | $309.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PRAX.
Shares short
3,795,697
Settlement Sep 15, 2026
Change vs prior
+1.5%
Semi-monthly cycle
Days to cover
14.9
At avg daily volume
Of shares outstanding
≈13.6%
Estimate — not % of float
All PRAX filing & press-release reports (10)
- 8-K reportJun 29, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportMay 7, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 14, 2026
- PRESS-RELEASE reportApr 6, 2026
- PRESS-RELEASE reportMar 30, 2026
- INST-CLUSTER reportFeb 28, 2026
- INST-CLUSTER reportFeb 28, 2026